vs

Side-by-side financial comparison of Riley Exploration Permian, Inc. (REPX) and TREACE MEDICAL CONCEPTS, INC. (TMCI). Click either name above to swap in a different company.

Riley Exploration Permian, Inc. is the larger business by last-quarter revenue ($97.3M vs $62.5M, roughly 1.6× TREACE MEDICAL CONCEPTS, INC.). On growth, Riley Exploration Permian, Inc. posted the faster year-over-year revenue change (-5.3% vs -9.0%). Over the past eight quarters, TREACE MEDICAL CONCEPTS, INC.'s revenue compounded faster (10.6% CAGR vs -1.2%).

Riley Exploration Permian, Inc. is an independent energy company focused on exploration, development, and production of crude oil, natural gas, and natural gas liquids primarily in the US Permian Basin spanning Texas and New Mexico. It prioritizes cost-efficient onshore reserve development to supply reliable energy products to North American markets.

Treace Medical Concepts, Inc. is a medical device company, headquartered in Ponte Vedra Beach, Florida, specializing in the design, manufacture, and marketing of foot and ankle surgical devices and biologics. Lapiplasty, Treace’s novel primary surgical product, advanced the treatment of bunions, surgically correcting the metatarsal bone, for the first time, in all three dimensions.

REPX vs TMCI — Head-to-Head

Bigger by revenue
REPX
REPX
1.6× larger
REPX
$97.3M
$62.5M
TMCI
Growing faster (revenue YoY)
REPX
REPX
+3.7% gap
REPX
-5.3%
-9.0%
TMCI
Faster 2-yr revenue CAGR
TMCI
TMCI
Annualised
TMCI
10.6%
-1.2%
REPX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
REPX
REPX
TMCI
TMCI
Revenue
$97.3M
$62.5M
Net Profit
$-9.4M
Gross Margin
80.6%
Operating Margin
26.9%
-9.5%
Net Margin
-15.0%
Revenue YoY
-5.3%
-9.0%
Net Profit YoY
-1775.0%
EPS (diluted)
$4.02
$-0.14

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
REPX
REPX
TMCI
TMCI
Q4 25
$97.3M
$62.5M
Q3 25
$106.9M
$50.2M
Q2 25
$85.4M
$47.4M
Q1 25
$102.5M
$52.6M
Q4 24
$102.7M
$68.7M
Q3 24
$102.3M
$45.1M
Q2 24
$105.4M
$44.5M
Q1 24
$99.7M
$51.1M
Net Profit
REPX
REPX
TMCI
TMCI
Q4 25
$-9.4M
Q3 25
$16.3M
$-16.3M
Q2 25
$30.5M
$-17.4M
Q1 25
$28.6M
$-15.9M
Q4 24
$-501.0K
Q3 24
$25.7M
$-15.4M
Q2 24
$33.5M
$-21.2M
Q1 24
$18.8M
$-18.7M
Gross Margin
REPX
REPX
TMCI
TMCI
Q4 25
80.6%
Q3 25
79.1%
Q2 25
79.7%
Q1 25
79.7%
Q4 24
80.7%
Q3 24
80.1%
Q2 24
80.2%
Q1 24
80.2%
Operating Margin
REPX
REPX
TMCI
TMCI
Q4 25
26.9%
-9.5%
Q3 25
27.0%
-31.2%
Q2 25
33.7%
-35.8%
Q1 25
48.3%
-29.6%
Q4 24
31.2%
-0.3%
Q3 24
17.1%
-33.6%
Q2 24
50.9%
-48.1%
Q1 24
50.7%
-37.1%
Net Margin
REPX
REPX
TMCI
TMCI
Q4 25
-15.0%
Q3 25
15.3%
-32.4%
Q2 25
35.7%
-36.7%
Q1 25
27.9%
-30.3%
Q4 24
-0.7%
Q3 24
25.1%
-34.1%
Q2 24
31.8%
-47.7%
Q1 24
18.8%
-36.5%
EPS (diluted)
REPX
REPX
TMCI
TMCI
Q4 25
$4.02
$-0.14
Q3 25
$0.77
$-0.26
Q2 25
$1.44
$-0.28
Q1 25
$1.36
$-0.25
Q4 24
$0.52
$-0.01
Q3 24
$1.21
$-0.25
Q2 24
$1.59
$-0.34
Q1 24
$0.94
$-0.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
REPX
REPX
TMCI
TMCI
Cash + ST InvestmentsLiquidity on hand
$48.4M
Total DebtLower is stronger
$247.9M
$55.6M
Stockholders' EquityBook value
$634.2M
$87.3M
Total Assets
$1.2B
$190.6M
Debt / EquityLower = less leverage
0.39×
0.64×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
REPX
REPX
TMCI
TMCI
Q4 25
$48.4M
Q3 25
$57.4M
Q2 25
$69.3M
Q1 25
$76.1M
Q4 24
$75.7M
Q3 24
$82.8M
Q2 24
$95.0M
Q1 24
$110.0M
Total Debt
REPX
REPX
TMCI
TMCI
Q4 25
$247.9M
$55.6M
Q3 25
$367.0M
$53.5M
Q2 25
$275.2M
$53.5M
Q1 25
$249.3M
$53.4M
Q4 24
$269.5M
$53.3M
Q3 24
$288.6M
$53.2M
Q2 24
$322.7M
$53.2M
Q1 24
$341.8M
$53.1M
Stockholders' Equity
REPX
REPX
TMCI
TMCI
Q4 25
$634.2M
$87.3M
Q3 25
$566.5M
$89.2M
Q2 25
$556.9M
$97.6M
Q1 25
$532.4M
$105.3M
Q4 24
$510.6M
$112.9M
Q3 24
$507.4M
$104.9M
Q2 24
$489.0M
$112.1M
Q1 24
$434.6M
$126.4M
Total Assets
REPX
REPX
TMCI
TMCI
Q4 25
$1.2B
$190.6M
Q3 25
$1.2B
$196.6M
Q2 25
$1.0B
$206.4M
Q1 25
$994.9M
$205.8M
Q4 24
$993.5M
$217.1M
Q3 24
$997.9M
$212.9M
Q2 24
$1.0B
$226.1M
Q1 24
$956.4M
$242.7M
Debt / Equity
REPX
REPX
TMCI
TMCI
Q4 25
0.39×
0.64×
Q3 25
0.65×
0.60×
Q2 25
0.49×
0.55×
Q1 25
0.47×
0.51×
Q4 24
0.53×
0.47×
Q3 24
0.57×
0.51×
Q2 24
0.66×
0.47×
Q1 24
0.79×
0.42×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
REPX
REPX
TMCI
TMCI
Operating Cash FlowLast quarter
$64.9M
$-8.0M
Free Cash FlowOCF − Capex
$-10.4M
FCF MarginFCF / Revenue
-16.7%
Capex IntensityCapex / Revenue
3.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-29.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
REPX
REPX
TMCI
TMCI
Q4 25
$64.9M
$-8.0M
Q3 25
$63.6M
$-9.1M
Q2 25
$33.6M
$-3.0M
Q1 25
$50.4M
$4.2M
Q4 24
$66.4M
$-4.2M
Q3 24
$72.1M
$-11.8M
Q2 24
$51.6M
$-13.9M
Q1 24
$56.1M
$-7.2M
Free Cash Flow
REPX
REPX
TMCI
TMCI
Q4 25
$-10.4M
Q3 25
$-11.9M
Q2 25
$-7.8M
Q1 25
$655.0K
Q4 24
$-7.3M
Q3 24
$-14.7M
Q2 24
$-15.6M
Q1 24
$-11.1M
FCF Margin
REPX
REPX
TMCI
TMCI
Q4 25
-16.7%
Q3 25
-23.7%
Q2 25
-16.5%
Q1 25
1.2%
Q4 24
-10.6%
Q3 24
-32.6%
Q2 24
-35.2%
Q1 24
-21.8%
Capex Intensity
REPX
REPX
TMCI
TMCI
Q4 25
3.8%
Q3 25
5.6%
Q2 25
10.1%
Q1 25
6.7%
Q4 24
4.5%
Q3 24
6.4%
Q2 24
3.9%
Q1 24
7.7%
Cash Conversion
REPX
REPX
TMCI
TMCI
Q4 25
Q3 25
3.90×
Q2 25
1.10×
Q1 25
1.76×
Q4 24
Q3 24
2.81×
Q2 24
1.54×
Q1 24
2.99×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons